Serodus ASA is a fast growing Norwegian cardio biopharma. The company announced today that it would merge with Phlogo ApS, a Danish peptide specialist. The merger would advance the commercialization of Serodus and would further develop its strategy with the addition of two first class drug candidates.

Chief Executive Officer of Serodus ASA Eva Steiness said that the company is delighted for the growth of its business through the merger. She also added that the merger would diversify the portfolio of Serodus' core cardiovascular therapeutic drug development field.  

Torben Skarsfeldt, Chief Executive of Phlogo ApS commented that the firm is very pleased with the merger. He added that the agreement with Serodus ASA to take over the business and its assets had generated very interesting data on both compounds. He said that Phlogo ApS needed additional resources to continue the development of its drugs. Further, he added that Serodus would bring more projects for Phlogo ApS.